-
Uncategorized4 weeks agoRoundup: Removing Impurities from Biomanufacturing
Effective impurity control is critical to biomanufacturing, supporting process, cell line, and formulation stability while preserving biotherapeutic potency and shelf life. Residual impurities can drive oxidation,...
-
Uncategorized4 weeks agoSTAT+: The IRS is probing UnitedHealth, and a private equity slowdown
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. Hello, everyone. Like usual, I’m writing to you from northwest Indiana....
-
Uncategorized4 weeks ago
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
-
Uncategorized4 weeks ago
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
Regeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile...
-
Uncategorized4 weeks agoSTAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we regale you with...
-
Uncategorized4 weeks ago
Your AI Is Only as Good as Your Inputs
Your AI Is Only as Good as Your Inputs
-
Uncategorized4 weeks ago
AstraZeneca pulls plug on late-stage lung cancer trial, extending losing streak
AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
-
Uncategorized4 weeks agoEverything the Trump administration did on health care last week
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning! Did you miss the newsletter last...
-
Uncategorized4 weeks ago
Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
Otsuka Pharmaceuticals’ Voyxact is not the only IgA nephropathy drug that can slow the decline of kidney function. Vera Therapeutics’ Trutakna, which the FDA granted accelerated...
-
Uncategorized4 weeks agoGlioblastoma therapy timing could be key to treatment
Scientists have identified a brief window after brain tumour surgery during which a treatment for glioblastoma can cross the brain’s protective barrier and reach the cancer...
FDA clears first generic radioligand drug; Sionna turns to layoffs
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
Ensuring safety and accountability in China’s biomedical translation system
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
